BioCentury
ARTICLE | Clinical News

FDA approves Orencia for psoriatic arthritis

July 13, 2017 2:27 AM UTC

FDA approved Orencia abatacept from Bristol-Myers Squibb Co. (NYSE:BMY) to treat psoriatic arthritis. The product is a CTLA-4 (CD152)-Ig fusion protein available in both IV and subcutaneous formulatio...

BCIQ Company Profiles

Bristol Myers Squibb Co.

BCIQ Target Profiles

CD80 (B7-1)

CD86 (B7-2)